These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25534724)

  • 1. Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.
    Bhansali SG; Mullane K; Ting LS; Leeds JA; Dabovic K; Praestgaard J; Pertel P
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1441-5. PubMed ID: 25534724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.
    Mullane K; Lee C; Bressler A; Buitrago M; Weiss K; Dabovic K; Praestgaard J; Leeds JA; Blais J; Pertel P
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1435-40. PubMed ID: 25534727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile.
    Sachdeva M; Leeds JA
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1252-7. PubMed ID: 25512411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
    Leeds JA; Sachdeva M; Mullin S; Barnes SW; Ruzin A
    J Antimicrob Chemother; 2014 Jan; 69(1):41-4. PubMed ID: 23887866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.
    Louie T; Nord CE; Talbot GH; Wilcox M; Gerding DN; Buitrago M; Kracker H; Charef P; Cornely OA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6266-73. PubMed ID: 26248357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers.
    Ting LS; Praestgaard J; Grunenberg N; Yang JC; Leeds JA; Pertel P
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5946-51. PubMed ID: 22964250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection.
    Thabit AK; Nicolau DP
    Int J Antimicrob Agents; 2015 Aug; 46(2):205-8. PubMed ID: 26055927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis.
    Beinortas T; Burr NE; Wilcox MH; Subramanian V
    Lancet Infect Dis; 2018 Sep; 18(9):1035-1044. PubMed ID: 30025913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
    Trzasko A; Leeds JA; Praestgaard J; Lamarche MJ; McKenney D
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4459-62. PubMed ID: 22644020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM; Spooner LM
    Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.
    Leeds JA
    Cold Spring Harb Perspect Med; 2016 Feb; 6(2):a025445. PubMed ID: 26834162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
    Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
    J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
    Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
    J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
    Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
    J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
    Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.
    Pettit NN; DePestel DD; Fohl AL; Eyler R; Carver PL
    Pharmacotherapy; 2015 Feb; 35(2):119-26. PubMed ID: 25689243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.